KRM Ayurveda IPO 2026: GMP, Lot Size & Investment Guide

KRM Ayurveda Limited is launching its SME IPO in January 2026, offering investors an opportunity to participate in a growing integrated Ayurvedic healthcare business that operates hospitals, clinics, wellness centers and teleconsultation services across India.

IPO Overview

IPO Opening Date: January 19, 2026
IPO Closing Date: January 21, 2026
Listing Date (Expected): January 27, 2026
Exchange: NSE EMERGE (SME platform)
Issue Type: Book Building IPO
Issue Size: Approx ₹77.49 crore
Fresh Issue Shares: 57,40,000 equity shares
Face Value: ₹10 per share
Price Band: ₹128 – ₹135 per share

This IPO is entirely a fresh issue, meaning proceeds will go to the company for growth and operations, rather than selling existing shares.

GMP (Grey Market Premium)

Grey Market Premium (GMP) refers to the informal, unofficial trading price of IPO shares before they list on the stock exchange. GMP helps gauge market sentiment and potential listing gains, but it’s not an official market price.

Current GMP for KRM Ayurveda IPO: ₹15 per share (indicative) (as per grey market trends)
Estimated listing price, based on GMP added to IPO price band, suggests a possible initial listing around ₹150 per share.
Note: GMP is unofficial and can change daily. It’s influenced by subscription levels and investor demand, not guaranteed.

Important: Investors should treat GMP as an indicative sentiment measure, not an assured listing outcome.

Lot Size & Minimum Investment

For the KRM Ayurveda IPO, the lot size and investment requirements are as follows:

Lot Size: 1,000 shares per lot
Minimum Application: 2 lots for retail investors
Minimum Investment (Retail): ₹2,70,000
Minimum Investment (S-HNI): 3,000 shares (₹4,05,000)
Minimum Investment (B-HNI): 8,000 shares (₹10,80,000)

Investors must bid in multiples of the lot size (1,000 shares) beyond the minimum.

This relatively high minimum investment is typical for SME IPOs and requires careful financial planning before applying.

Business & Growth Background

KRM Ayurveda operates in the AYUSH healthcare segment, focusing on Ayurvedic medical treatments, wellness programs, and related services. Its business model includes:

Network of hospitals and clinics in major Indian cities
Teleconsultation services, enabling remote patient care
Ayurvedic therapies including Panchakarma, chronic disease management, preventive care, and lifestyle programs

The company aims to use the IPO proceeds for expansion, including:

Development of telemedicine facilities
CRM and IT infrastructure
Working capital and loan repayment
Scaling operations and human resources

Financial Details (Indicative)

Most SME IPO analyses highlight the company’s recent performance trends — including revenue and profitability growth — which factors into investor interest and GMP movement. Although detailed audited figures are best checked in the official prospectus, available summaries indicate:

Growing revenue trends
Net profit improvement year-on-year
Healthy EBITDA and return ratios relative to SME peers

Risks to Consider

Investors should be aware of potential risks before applying:

Operational risks due to leased properties (non-owned hospital premises)
Geographical concentration of revenue
High employee attrition potential
Dependency on third-party insurance and schemes
Legal & compliance exposures typical in healthcare service businesses

Being SME listed, liquidity may be lower initially compared to mainboard stocks — this can affect trading volumes post-listing.

Should You Apply?

Good For:

Investors seeking listing gains (short-term) if GMP remains positive
Those who believe in AYUSH & wellness sector growth
Long-term investors aiming to hold quality SME stocks

Consider:

High entry ticket: ₹2.7 lakh minimum for retail
SME stocks may have higher volatility and limited liquidity
GMP insights are indicative, not guaranteed returns

Conclusion

The KRM Ayurveda IPO presents a promising opportunity in the evolving AYUSH healthcare space. Investors eyeing short-term gains should monitor GMP trends and subscription levels, while long-term investors should review the company’s business fundamentals, risks, and future growth plans before applying.